JNJ and LLY Related Headlines
Go Back- Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight
- Goldman Sachs: 'top themes we're tracking for 2026'
- Trump to announce prescription drug price agreements
- Biotech Valuations Rise as New Clinical Platforms Show Progress
- Vida Ventures Marks Fourth Major Portfolio Acquisition in 2025, Capping a Record-Setting Year for Its Science-Led, Discipline-Driven Strategy
- Canaccord #1 Key Risk to AxoGen, Inc. (AXGN): 'the FDA running out of carryover funding and needing to halt work'
- FDA on Operations During Shutdown: 'FDA will not be able to accept any regulatory submissions for FY 2026 that require a fee payment'
- Trump on deal with Pfizer: we're going to be paying the lowest price, other drugmakers will commit in coming weeks
- Buy this U.S. large-cap biopharma stock: JPMorgan
JNJ and LLY Related Press Releases
Go Back- Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight
- Biotech Valuations Rise as New Clinical Platforms Show Progress
- Vida Ventures Marks Fourth Major Portfolio Acquisition in 2025, Capping a Record-Setting Year for Its Science-Led, Discipline-Driven Strategy
